Abstract
Background Neurofibromatosis 1 (NF1) is a rare, neurogenetic disorder predisposing individuals to central and peripheral nervous system tumors, as well as a wide range of other physical, neurocognitive, and psychosocial issues. Regular health monitoring throughout the lifespan is needed to identify these heterogenous disease complications, but the degree to which this is implemented in routine clinical practice is unknown. This, this study aimed to investigate U.S. patients’ access to specialized NF1 clinics and receipt of evidence-informed health surveillance.
Methods An online cross-sectional survey was distributed in May 2021 to adults with NF1 and parents of children with NF1 enrolled in the NF Registry (n=6908). Rate of NF1 clinic attendance and self-reported receipt of health surveillance amongst all NF Registry participants was estimated using inverse propensity scores. Differences in these outcomes based on participant demographics were assessed using weighted logistic regression and robust linear regression, respectively.
Results 322 individuals responded (160 adults, 162 parents; 4.7% overall response rate). We estimate that 51.7% of children and 35.6% of adults attend NF1 clinics. Younger children were more likely to attend an NF1 clinic, as were adults living in urban areas, with a college degree or higher, or with a household income ≥$130,000 (all ps<0.05). Completion rates for each individual health surveillance evaluation ranged from 41%-79% for children and 33%-61% for adults. Higher rates of recommended evaluations were reported by both adults and children who attend a specialized NF1 clinic, non-Hispanic White adults, and adults with commercial or Medicare insurance (all ps<0.05).
Discussion Adults with NF1 experience significant sociodemographic disparities in care, and patients of all ages attending NF1 specialty clinics receive more recommended health surveillance. Given the limited access to specialty NF clinics, quality improvement efforts are needed to increase access for underserved adults and improve provision of recommended health surveillance outside specialty clinics.
Competing Interest Statement
Ms. Kelts and Ms. Radtke are employees of the Childrens Tumor Foundation, which administers the NF Registry and NF Clinic Network. While unrelated to the submitted work, the following authors have financial associations with commercial entities as described: Dr. Yohay has served as consultant and speaker for Alexion. Dr. Ullrich receives royalties from UpToDate, has received compensation for non-branded lectures for Alexion Therapeutics, and has provided expert testimony for Wolf, Horowitz & Etlinger, LLC. Dr. Plotkin is co-founder of NFlection Therapeutics and NF2 Therapeutics and has consulted for Akouos. Dr. Jordan has received consulting income from Alexion pharmaceuticals, Springworks pharmaceuticals, Shepherd Therapeutics, Navio Theragnostics, Magnet Biomedicine, Recursion Pharmaceuticals, Merck Pharmaceuticals, and Akeila Bio. He also has equity in Akeila Bio, Navio Theragnostics, and The Doctor Lounge. The remaining authors have no competing interests or financial associations with commercial entities.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Western Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data may be requested from the NF Registry by emailing nfregistry{at}ctf.org. All requests are reviewed by the NF Registry Data Access Committee to ensure appropriate scientific and ethical use of the data.
